ISTA Pharmaceuticals has announced results from a Phase 2 randomized, placebo-controlled, parallel-group environmental clinical study of its Beposone bepotastine besilate/steroid nasal spray for the treatment of seasonal allergic rhinitis. According to the company, the study showed that Beposone produced statistically significant improvements in nasal symptoms of … [Read more...] about Positive Phase 2 topline results for ISTA’s Beposone nasal spray
Medical
Asmanex Twisthaler shortage
The FDA issued a drug shortage alert for the Asmanex Twisthaler 110 mcg mometasone furoate inhalation Powder, 30 inhalation units, as of April 26, 2012. According to the FDA web site, the shortage is due to manufacturing delays and the expected duration is unknown. The 110 mcg dose Asmanex Twisthaler is recommended for the treatment of asthma in children ages 4-11 … [Read more...] about Asmanex Twisthaler shortage
Savara’s AeroVanc inhaled vancomycin well tolerated in Phase 1a study
Savara Pharmaceuticals has announced top-line data from a Phase 1a study of its AeroVanc vancomycin hydrochloride inhalation powder for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients. According to the company, the study, which compared single ascending doses of AeroVanc with intravenous vancomycin in healthy … [Read more...] about Savara’s AeroVanc inhaled vancomycin well tolerated in Phase 1a study
Novartis expected to file NDAs for QVA149 and NVA237 in 2014
According to Sosei, Novartis and the FDA have agreed on Phase 3 trial design for QVA149 indacaterol/glycopyrronium bromide and NVA237 glycopyrronium bromide, which should put the company on track to file an application for NVA237 early in 2014 and an application for QVA149 by the end of that year. Novartis licensed NVA 237 from Sosei and Vectura. Both Sosei and … [Read more...] about Novartis expected to file NDAs for QVA149 and NVA237 in 2014
MicroDose Therapeutx completes Phase 1 studies of inhaled antiviral fusion inhibitor for RSV
Two Phase 1 studies of MDT-637 inhaled antiviral fusion inhibitor for the treatment of RSV infection have demonstrated that the drug is well tolerated and causes no significant changes in lung function, MicroDose Therapeutx has announced. The double-blind, randomized, placebo-controlled dose-ranging studies also showed that MDT-637 reached the respiratory tract at … [Read more...] about MicroDose Therapeutx completes Phase 1 studies of inhaled antiviral fusion inhibitor for RSV
Synairgen announces positive Phase 2 results for inhaled interferon beta
UK-based Synairgen has announced positive data from a Phase 2 trial of its SNG001 inhaled interferon beta as protection against the common cold and other respiratory viral infections in asthma patients. According to the company, SNG001 showed statistically significant improvements compared to placebo in prevention of symptom worsening during the first week of … [Read more...] about Synairgen announces positive Phase 2 results for inhaled interferon beta
Positive Phase 1 results for dry powder intranasal zolmitriptan
Shin Nippon Biomedical Laboratories has announced results from a Phase 1 study of its intranasal zolmitriptan formulation (TRZ) for the treatment of migraine headaches. The company is developing several intranasal drugs based on its μco muco-adhesive powder carrier system and intranasal powder delivery device. According to SNBL, the study, which compared three … [Read more...] about Positive Phase 1 results for dry powder intranasal zolmitriptan
Pearl Therapeutics creates nanogram-dose MDIs
According to Pearl Therapeutics, the company has produced metered dose inhalers (MDI) with the ability to deliver a 300ng dose of glycopyrrolate (GP) per actuation. Pearl formulated the GP for the nanogram-dose inhalers using the company's porous particle cosuspension technology and has initiated a Phase 2b study to evaluate safety and efficacy of twice a day dosing … [Read more...] about Pearl Therapeutics creates nanogram-dose MDIs
QVA 149 Phase 3 studies meet primary endpoints
Three Phase 3 studies of Novartis's QVA149 indacaterol /glycopyrronium bromide dry powder inhaler for the treatment of COPD have met their primary endpoints according to the company. The SHINE study demonstrated superiority in trough FEV1 for QVA 149 compared to indacaterol alone, glycopyrronium alone, tiotropium, and placebo in more than 2,000 patients with moderate … [Read more...] about QVA 149 Phase 3 studies meet primary endpoints
Almirall publishes full results from aclidinium bromide study
Almirall has published full results from the ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts) study in The European Respiratory Journal (ERJ). ATTAIN was a six-month double-blind placebo-controlled study that compared two doses of inhaled aclidinium (200μg and 400μg twice daily) to placebo in patients with COPD. According to the company the 400 µg dose … [Read more...] about Almirall publishes full results from aclidinium bromide study